Patent Dispute Ends: Genentech and Abbott Laboratories...

Patent Dispute Ends: Genentech and Abbott Laboratories have agreed to drop their counter claims over two Abbott patents on a substance known as plasminogen activator. Genentech, of South San Francisco, said the out-of-court settlement means that it can continue unrestricted sales of its tissue plasminogen activator, a drug for treatment of heart attack victims.